Biocompatibles to return £100 million to shareholders
This article was originally published in Clinica
Biocompatibles plans to give shareholders back around £100 million ($143 million) following criticism from analysts and investors about the company's planned sale of its coronary stent business to Abbott for $235 million (see Clinica No 1001, p 15). At the same time, the UK company has been named co-defendant in a lawsuit filed by US company Isostent.
You may also be interested in...
To be more transparent and allow more public discourse, the HHS now requires all its agencies to publish documents it uses to rationalize proposed rules and demonstration projects.
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.